GEN · May 2026
Coverage of ParcelBio’s APEXm platform, the seed financing, and its planned ASGCT debut with preclinical data on durable mRNA expression and in vivo CAR-T.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
ParcelBio is a San Francisco biotech developing APEXm™, a next-generation mRNA platform designed to drive more durable, higher protein expression; its lead programs focus on in vivo CAR-T for autoimmune disease, plus oncology and encoded protein therapeutics.
Primary product
APEXm™ (Amplified and Prolonged EXpression mRNA) platform
Founded
2023
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
mRNA therapeutics
Offices
135 Mississippi Street, San Francisco, CA 94107, United States
Open Positions
0 jobs at ParcelBio
No open positions
Check back later for new openings